A Phase 2 interventional study of repetitive transcranial magnetic stimulation in Alcohol Use Disorder, Mild Traumatic Brain Injury and Post-traumatic Stress Disorder, sponsored by VA Office of Research and Development. Terminated at 1 site in United States. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment
COVID and funding
Herrold AA, Siddiqi SH, Livengood SL, Bender Pape TL, Higgins JP, Adamson MM, Leung A, Raij T. Customizing TMS Applications in Traumatic Brain Injury Using Neu…PubMed 33165153 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Alcoholism by VA Office of Research and Development — 7 open to participants now, 9 under way, 2 of them phase 3. Alcoholism · VA Office of Research and Development.
Among the 47 studies in Alcoholism by VA Office of Research and Development, this one is the 41st largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2019, is one of 6 in phase 2, and was the 31st registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →7 of the 47 studies in Alcoholism by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18–80 · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 21–65
VA Office of Research and Development · Sites in United States
Ages 18–80
VA Office of Research and Development · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 22 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 5 · Phase 4 3
First in 2005; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 96 across the 42 interventional studies, 318 across the 5 observational. Of the 37 that completed or were terminated, 33 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
2 of the studies in Alcoholism by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05372029VA Office of Research and DevelopmentAAT for Alcohol Use Disorder in Veterans | 2027-01-01 |
| NCT04043442VA Office of Research and DevelopmentrTMS Target Identification for Functional Disability in AUD+mTBI | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 47 studies in Alcoholism by VA Office of Research and Development, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a pilot randomized controlled trial (RCT) for Veteran participants with alcohol use disorder co-occurring with mild traumatic brain injury and/or post-traumatic stress disorder. The treatment intervention is repetitive Transcranial Magnetic Stimulation (rTMS) and the goal is to reduce alcohol craving with this treatment. The study will enroll 20 Veteran participants. Half of these participants will receive real rTMS and half of the participants will receive placebo rTMS. rTMS treatment will be provided over 10 sessions that will occur once every weekday for 2 weeks. Veteran participants will then complete follow-up phone calls to further evaluate alcohol craving and other symptoms.
Mild traumatic brain injury (mTBI), post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) are high priority disorders for the Department of Veterans Affairs (VA), in part, because these disorders rarely occur in isolation. The co-occurrence compounds brain impairment and negatively impacts symptom presentation and rehabilitation effectiveness. Veterans with co-occurring AUD, mTBI and/or PTSD have few effective treatment options. Thus, treatment development for these Veterans is of great need. The aim of this protocol is to examine safety, feasibility, and the behavioral and neural effects of an repetitive transcranial magnetic stimulation (rTMS) intervention for Veterans with AUD and co-occurring mTBI and/or PTSD. Behavioral and neural effects of rTMS will be examined after the first rTMS session and after the last rTMS session. The investigators hypothesize that the rTMS intervention will be 1) safe, 2) feasible and 3) efficacious. Specifically, the investigators hypothesize that there will be no adverse events related to the rTMS intervention. The investigators hypothesize that all participants enrolled will successfully complete all rTMS sessions. The investigators hypothesize that participants treated with active rTMS, relative to placebo rTMS, will have reduced alcohol craving severity levels. Finally, the investigators hypothesize that participants treated with active rTMS relative to placebo rTMS will have reduced brain activation in response to alcohol cues and improved functional connectivity after the last rTMS session. This is a prospective, pilot, double-blind randomized controlled trial of the intervention rTMS. There will be 2 groups of Veterans with AUD and co-occurring mTBI and/or PTSD those given 1) active rTMS and those given 2) placebo rTMS. Targeted enrollment for this study is 20 Veterans: n=10 active rTMS and n=10 placebo rTMS. Participants will be screened for safety and evaluated on mental health-related behavioral measures. Eligible participants will be randomized to receive active or placebo rTMS. Participants will then complete motor thresholding (MT) to determine rTMS intensity. Participants will then complete 10 sessions of rTMS. These sessions will be completed once daily on week days over two weeks. TMS pulses will be applied to the left DLPFC at 10Hz rate, 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session. After the 10th rTMS session, participants will complete an MRI which will last approximately 1hour. A sub-sample of participants will complete an MRI immediately after the first rTMS session. Participants will also repeat the mental health behavioral measures after the last rTMS session. Participants will complete follow-up phone interviews to assess for alcohol craving, mTBI symptoms and PTSD symptoms at one day, one week and one month post-rTMS. Completion of this study is an essential first step towards treatment development for Veterans with co-occurring AUD, mTBI and/or PTSD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Current use of:
Currently prescribed any anti-craving/addiction medications, i.e.:
Have cardiac pacemaker or defibrillator, or:
History of:
active rTMS
Device: repetitive transcranial magnetic stimulation
placebo rTMS
Device: repetitive transcranial magnetic stimulation
rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P). The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
Also known as: transcranial magnetic stimulation
Total Adverse Event Frequency
An adverse event log will be kept for each participant and each rTMS treatment session. After each treatment these events will be recorded and the total frequency of events will be used as the outcome after all 10 rTMS sessions over the course of the 2 week treatment have been completed.
Time frame: immediately after last/10th rTMS session - up to 2 weeks
Total rTMS Sessions Completed
Total number of rTMS treatment sessions completed out of 10 sessions. After all 10 rTMS sessions over the course of the 2 week treatment this cumulative total number of sessions complete can be computed.
Time frame: after the 10th and last rTMS treatment session - up to 2 weeks
Penn Alcohol Craving Scale
Penn Alcohol Craving Scale. Self report measure of 5 questions rated on a scale of 0-6, with higher scores indicating more severe craving. Minimum possible total score is 0 and maximum possible total score is 30, with higher scores indicating more severe craving.
Time frame: baseline (pre-treatment), immediately after last/10th TMS session, approximately 2 weeks later
Veterans that previously participated in previous IRB-approved studies on AUD+mTBI and who consented to be enrolled in a IRB-approved TBI data repository will be invited to participate. Veterans were mailed invitational letters with an opt-out card, and if an opt-out card wasn't received, then a follow-up phone call was made for recruitment and screening. No more than 2 voice messages and 3 phone calls will be made.
| Milestone | Active | Placebo |
|---|---|---|
| Started | 0 | 1 |
| Completed | 0 | 1 |
| Not completed | 0 | 0 |
An adverse event log will be kept for each participant and each rTMS treatment session. After each treatment these events will be recorded and the total frequency of events will be used as the outcome after all 10 rTMS sessions over the course of the 2 week treatment have been completed.
| Count of Adverse Events | Active | Placebo |
|---|---|---|
| Total Adverse Event Frequency | — | 1 |
Total number of rTMS treatment sessions completed out of 10 sessions. After all 10 rTMS sessions over the course of the 2 week treatment this cumulative total number of sessions complete can be computed.
| Number of sessions completed | Active | Placebo |
|---|---|---|
| Total rTMS Sessions Completed | — | 10 |
Penn Alcohol Craving Scale. Self report measure of 5 questions rated on a scale of 0-6, with higher scores indicating more severe craving. Minimum possible total score is 0 and maximum possible total score is 30, with higher scores indicating more severe craving.
| score on a scale | Active | Placebo |
|---|---|---|
| baseline, pre-treatment | — | 3 |
| immediately after last/10th TMS session, approximately 2 weeks later | — | 1 |
Collected over from beginning of TMS treatment until after the last rTMS treatment, up to 2 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active | — | — | — |
| Placebo | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Active | Placebo |
|---|---|---|
| eye blinking and transient blurriness and seeing black dots, likely due to dry eyesEye disorders | — | 1/1 |
Two participants were enrolled, one was randomized and had baseline data collected.
| Age, Categorical(Participants) | Active | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 1 | 1 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Active | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Active | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Active | Placebo | Total |
|---|---|---|---|
| United States | — | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Mar 2020, 12 months.
Results were first posted in Oct 2026, 6 years 6 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Mar 2026 → Mar 2020 and completion Mar 2026 → Mar 2020.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
COVID and funding
Herrold AA, Siddiqi SH, Livengood SL, Bender Pape TL, Higgins JP, Adamson MM, Leung A, Raij T. Customizing TMS Applications in Traumatic Brain Injury Using Neu…PubMed 33165153 ↗
COVID and funding
Herrold AA, Siddiqi SH, Livengood SL, Bender Pape TL, Higgins JP, Adamson MM, Leung A, Raij T. Customizing TMS Applications in Traumatic Brain Injury Using Neu…PubMed 33165153 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VA Office of Research and Development →